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This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. A total of 221 Japanese patients who
received gefitinib (250mgday
 1) were examined retrospectively and potential predictive factors analysed. Overall response rate
(ORR) was 24.4% and median survival time (MST) was 8.0 months. In a log-rank test, survival was significantly better in females,
patients with adenocarcinoma, never-smokers, favourable performance status (PS) and patients with epidermal growth factor
receptor (EGFR) mutation. The lower the smoking exposure (Brinkman Index (BI)¼cigarettes per day years smoked), the better
the MST (BI 0: 14.5 months, BI o500: 9.5 months, BI 500 to o1000: 6.9 months, BI X1000: 4.0 months). Positive-EGFR mutation
status and PS 0–1 were independent predictors of favourable prognosis by multivariate analysis. Prognosis was significantly different
according to EGFR mutation status (with the same smoking status), but not according to smoking status (with the same EGFR
mutation status). EGFR mutation status is the most important independent predictor of survival benefit with gefitinib treatment.
Although differences in prognosis were observed according to relative smoking status and smoking exposure, the results suggested
that smoking is not a direct predictor of prognosis, yet is a surrogate marker of EGFR mutation status.
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Gefitinib (IRESSA) is an orally active small-molecule compound
that inhibits the epidermal growth factor receptor (EGFR) tyrosine
kinase (TK) by competing with adenosine triphosphate (ATP) at
the ATP-binding site. In two large Phase II trials (IDEAL: IRESSA
Dose Evaluation in Advanced Lung cancer 1 and 2) gefitinib-
induced tumour regression and provided symptom relief in
previously treated patients with non-small-cell lung cancer
(NSCLC) (Fukuoka et al, 2003; Kris et al, 2003). Although a
placebo-controlled Phase III study (ISEL) in previously-treated
patients with NSCLC has not shown a statistically significant
improvement in survival associated with gefitinib, preplanned
subgroup analysis suggested survival benefits in patients of Asian
origin and never-smokers (Thatcher et al, 2005). Patient selection
criteria were not incorporated in this comparative study, which
most likely contributed to the absence of a positive survival benefit
in the overall population. In fact, a Phase II study in which
gefitinib was used as first-line therapy for NSCLC in a subgroup
of never-smokers with adenocarcinoma reported favourable out-
comes, with an overall response rate (ORR) of 61% (Lee et al,
2005).
In 2004, mutations in the EGFR gene conferring increased
sensitivity to gefitinib were reported (Lynch et al, 2004; Paez et al,
2004). Recently, very favourable outcomes (response rate (RR)
75%) in a Phase II study of gefitinib as first-line therapy for
patients with NSCLC with EGFR gene mutations has been reported
(Inoue et al, 2006).
Therefore, it is important to conduct patient selection before
using gefitinib and, in particular, it is vital to identify the
predictive factors that may contribute to survival. To aid future
selection of patient groups for gefitinib treatment we conducted a
retrospective analysis of patients who had been treated with
gefitinib, assessing the relationship between clinical character-
istics, the EGFR mutation status, antitumour activity and patient
survival.
PATIENTS AND METHODS
Patients
A total of 221 patients who had been initiated on gefitinib
monotherapy (250mgday
 1) during a 3-year span from July 2002
(gefitinib was launched in Japan) to June 2005 at the Hyogo
Medical Center for Adults in Japan were retrospectively examined.
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sClinical assessments
Clinical parameters studied were gender, age, smoking history
(Brinkman Index (BI)¼number of cigarettes per day number of
years smoked), Eastern Cooperative Oncology Group performance
status (PS) and previous lines of chemotherapy.
Assessment of tumour regression was conducted according to
the response evaluation criteria in solid tumours (RECIST)
guideline. The National Cancer Institute Common Toxicity
Criteria, version 3.0, was used to evaluate toxicity.
EGFR gene analysis
EGFR gene mutation detection was performed on samples from
106 patients: surgical specimens were obtained from 34 patients
and a transbronchial lung biopsy (TBLB) was performed on 72
patients. EGFR mutation analysis was successfully performed in 91
of the 106 samples. EGFR mutation was analysed at Aichi Cancer
Center Hospital in Japan. A cycleave PCR technique for codon 858
of EGFR gene was used on a SmartCycler system (SC-100, Cepheid,
Sunnyvale, CA, USA). Deletion in exon 19 of the EGFR gene was
detected with fragment analysis using an ABI PRISM 310 genetic
analyzer (Applied Biosystems, Foster City, CA, USA) (Yatabe et al,
2006). Many of the cases began treatment on gefitinib before it had
been reported that EGFR mutation detection was important when
treating with the drug. Moreover, many of those cases had already
died before our plans to undergo EGFR mutation detection,
effectively preventing us from obtaining informed consent in this
regard. Accordingly, our Institutional Review Board approved
our study plan, provided that samples would be processed
anonymously, that samples would be analysed only for somatic
mutations and not germline mutations, and that the presence of
the study be publicly disclosed, strictly according to the ‘Ethical
Guidelines for Human Genome Research’ published by The
Ministry of Education, Culture, Sports, Science and Technology,
The Ministry of Health, Labour and Welfare and The Ministry of
Economy, Trade and Industry, Japan. (http://www.mext.go.jp/
a_menu/shinkou/seimei/genome/04122801.htm).
Statistical analysis
OS analysis was conducted on all 221 and 91 patients in which
EGFR mutation analysis could be successfully performed.
The differences in responders (complete response; CRþpartial
response; PR) by each factor (gender, PS, histology, prior
chemotherapy, smoking status and mutation status) were exam-
ined with the Fisher’s exact test. The difference in mutation rate
among groups categorised by smoking exposure was examined
with w
2 test.
An OS curve was plotted using the Kaplan–Meier method and
survival curve comparisons were conducted with the log-rank test.
Univariate analysis and multivariate analysis of the impact of the
factors, including gender (male vs female), smoking history (ever-
smokers vs never-smokers), histology (adenocarcinoma vs others),
PS (PS 0–1 vs 2–4) and EGFR mutation (positive vs negative) were
conducted using the Cox regression model. All analysis was
determined to be statistically significant where the P-value was
o0.05.
Analyses were conducted using the SPSS 11.0.1.
RESULTS
Patient characteristics
The clinical characteristics of the patients are shown in Table 1.
The majority of patients (89%) had adenocarcinoma histology.
One hundred and thirty-one patients (59%) were ever-smokers.
EGFR mutation analysis and clinical response
TBLB or surgical samples were available from 106 patients for
EGFR-mutation detection, but actual analysis was only possible for
103 patients because tumour cells were not found in three post-
treatment specimens.
DNA could not be amplified in 12 cases. Analysis of the
remaining 91 samples showed EGFR mutations in 28 patients
(30.8%) and wild type in 63 patients (69.2%). EGFR mutation rate
was high in females, never-smokers and patients with adenocarci-
noma. Among ever-smokers, EGFR mutation rate was higher in
patients with BIo500 and BI 500 to 1000 than BI 41000 (Table 2).
Of the 28 EGFR mutations, 19 (67.9%) were exon 19 in-frame
deletions and nine (32.1%) were exon 21-point mutations (L858R).
Seven (36.8%) of the exon 19 deletions and four (44.4%) of the
L858R cases were smokers. Significantly high mutation rates were
observed in females and never-smokers.
In the overall population, RR was 24.4% (95% confidence
interval (CI) 18.0–30.6%) (Table 1). Response rate was signifi-
cantly higher among females, patients with adenocarcinoma
histology, never-smokers and patients with the EGFR mutation.
Disease control rate (DCR: CRþPRþstable disease; SD) was
51.1% (95% CI 44.3–57.9%) and among those with EGFR
mutation, 100%.
Survival analyses
Median survival time (MST) in the overall population was 8
months, with 34.8% surviving 1 year. MST among patients
showing PR was significantly longer than that in the SD cases
(P¼0.003) and MST of the SD cases was also shown to be
significantly longer than that of the PD cases (Po0.0001) (Table 1).
Kaplan–Meier curves indicated significantly longer survival
in patients with favourable PS (Po0.0001), in patients with
adenocarcinoma histology (Po0.0001), in never-smokers
(Po0.0001), and in patients with EGFR mutations (Po0.0001)
(Table 1, Figure 1). L858R patients tend to survive longer than
those with deletions at exon 19 (P¼0.0539). Multivariate analysis
was conducted to identify factors contributing to survival. When
all patients were analysed considering of the clinical characteristics
(gender, adenocarcinoma histology, smoking status and PS),
adenocarcinoma, never-smoker status and PS 0–1 were found to
be prognostic factors of survival (Table 3a). However, analysis
(including that on EGFR mutation status and clinical charac-
teristics) of the patients for whom EGFR mutation results were
obtained showed PS 0–1 and EGFR gene mutation status to be the
independent prognostic factors, and the relationship between
smoking status and survival did not reach statistical significance
(Table 3b).
Further analysis of smoking exposure and survival indicated
that the higher the exposure, the shorter the MST (Figure 2) . The
presence of EGFR mutation was associated with significantly
prolonged survival in both never-smokers (P¼0.014) and ever-
smokers (P¼0.012). Furthermore, among EGFR mutation-positive
patients, there was no statistically significant difference in median
survival between never-smokers and ever-smokers (P¼0.864),
although patient numbers were small (Figure 3).
Tolerability
Adverse events were observed in 165 out of 221 (75%) patients.
Common adverse events were rash/dry skin (51%), diarrhoea
(22%), liver dysfunctions (20% (2.3% were Grade 3)) and
paronychia (14%). Sixteen (7%) of the patients developed
interstitial lung disease (ILD) and three (1.4%) died. As three
out of 14 (21%) patients with PS 3 developed ILD, patients with
poorer PS were more likely to develop ILD. There were no
differences in ILD incidence by gender, smoking history, age or
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type and two out of 28 patients with EGFR mutation (both with an
exon 19 deletion).
DISCUSSION
The data from this retrospective study suggest that in a practical
setting
(1) A favourable PS, adenocarcinoma histology, never-smoking
and presence of an EGFR mutation are predictive of increased
antitumour activity with gefitinib,
(2) Although PR cases showed longer median survival than SD
cases, SD cases also displayed significantly longer median
survival than PD cases,
(3) Although, in terms of clinical characteristics, PS 0–1,
adenocarcinoma histology and never-smoking status are
predictive factors of survival with gefitinib in the overall
population, PS 0–1 and EGFR mutation status were identified
as independent predictive factors in patients in which EGFR
mutation status has been detected,
(4) The relationships between smoking/EGFR mutation status and
survival suggest that the latter is more related to prognosis.
Conceivably, smoking has a strong confounding relationship
with EGFR mutation status and smoking exposure can result
in a different prognosis.
IDEAL 1 reported favourable antitumour activity in females and
patients with adenocarcinoma histology (Fukuoka et al, 2003).
Table 1 Demographics and relationship between clinical variables and antitumor response/overall survival in patients treated with gefitinib
Characteristic No. of patients (%) PR (n) RR (%) (95% CI) P-value* MST (months) (95% CI) P-value
All 221 54 24.4 (18.9–30.6) 8 (6.66–9.34)
Gender
Male 142 (64) 20 14.1 (8.8–20.9) o0.001 6.8 (5.04–8.56) 0.036
Female 79 (36) 34 43 (31.9–54.7) 13.3 (8.84–17.76)
Age
65o 100 20 20 (12.7–29.2) 0.208 9 (6.41–11.59) 0.2852
o65 121 34 28.1 (20.3–37.0) 7.3 (5.88–8.72)
ECOG PS
0–1 160 (72) 44 27.5 (20.7–35.1) 0.114 11.1 (8.30–13.90) o0.001
2–4 61 (28) 10 16.4 (8.2–28.1) 2.1 (1.26–2.94)
Histology
Adenocarcinoma 196 (89) 52 26.5 (20.5–33.3) 0.048 9.3 (7.66–10.94) 0.137
Others 25 (9) 2 8 (1.0–26.0) 3.6 (2.13–5.07)
Prior chemotherapy
Yes 188 (85) 45 24.6 (18.5–43.3) 1 8.1 (6.67–9.53) 1
No 33 (15) 9 25.7 (12.5–43.3) 8.4 (5.72–11.08)
Smoking history (n¼220)
No 89 (40) 37 41.6 (31.2–52.5) o0.001 14.5 (10.87–18.13) o0.001
Yes 131 (15) 17 13 (7.7–20.0) 6.5 (4.36–8.64)
BI 1o500 25 (11) 5 20 (6.8–40.7) 9.5 (6.41–12.59)
BI 500 to o1000 59 (27) 9 15.3 (7.2–27.0) 6.9 (5.64–8.16)
BIX1000 45 (21) 2 4.4 (0.5–15.1) 4 (3.00–5.00)
EGFR gene status (n¼91)
Wild type 63 (69) 7 11.1 (4.6–21.6) o0.001 7.4 (4.84–9.96) o0.001
Mutation positive 28 (31) 20 71.4 (51.3–86.8) 24.9 (14.27–35.53)
Exon 19 deletion 19 (21) 15 78.9 (54.4–93.9) 16.1 (6.22–25.98)
Exon 21 (L858R) 9 (10) 5 55.6 (21.2–86.3) 434.5 —
Tumor response (n¼191)
PR 54 — — 26.2 (15.76–36.64) 0.003
SD 59 — — 11.9 (7.47–16.33) o0.0001
PD 78 — — 5.6 (3.20–8.00)
Abbreviations: BI¼Brinkman Index; BI¼defined as number of cigarettes per day number of years smoking; CI¼confidence interval; EGFR¼epidermal growth factor
receptor; ECOG PS¼Eastern Cooperative Oncology Group performance status; MST¼median survival time; PD¼progressive disease; PR¼partial response; RR¼response
rate; SD¼stable disease.*Fisher’s exact test.
Table 2 Mutation rate by patient background
Population N Mutation (%) 95%CI P-value
a
All samples 91 28 (30.8)
Male 59 12 (20.3) 11.0–32.8 0.005
Female 32 16 (50.0) 31.9–68.1
Never-smoker 38 17 (44.7) 28.6–61.7 0.014
Ever-smoker 53 11 (20.8) 10.8–34.1
Adeno 81 27 (33.3) 23.2–44.7 0.166
Non-adeno 10 1 (10.0) 0.3–44.5
Brinkman Index
0 38 17 (44.7) 28.6–61.7 0.055
b
15500 9 2 (22.2) 2.8–60.0
50051000 25 7 (28.0) 12.1–49.4
1000o 18 2 (11.1) 1.4–34.7
aFisher’s exact test (two-sided).
bw
2-test (likelihood ratio).
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sSeveral subsequent retrospective studies have reported that female
gender, adenocarcinoma histology, bronchioloalveolar subtype,
never-smokers and patients with favourable PS are predictive
factors of response (Miller et al, 2004; Kim et al, 2005; Lim et al,
2005; Ando et al, 2006). EGFR mutation has been reported as a
predictor of efficacy of gefitinib and erlotinib (Lynch et al, 2004;
Pao et al, 2004). There have been several reports of clinical factors
associated with EGFR mutations, and per the univariate analysis,
mutation frequency is high in patients of East Asian ethnicity,
females, never-smokers and adenocarcinomas (Kosaka et al, 2004;
Paez et al, 2004; Shigematsu et al, 2005; Tokumo et al, 2005).
Moreover, multivariate analysis has shown that adenocarcinoma
histology and never-smoker status are independent factors
associated with EGFR mutation (Kosaka et al, 2004; Tokumo
et al, 2005). Reports to date have shown that approximately 90% of
EGFR mutations are centred around the L858R point mutation in
exon 21 and deletions centred around codons 746–750 in exon 19
(Kosaka et al, 2004; Shigematsu et al, 2005; Sonobe et al, 2005;
Tokumo et al, 2005). As association between these two types of
EGFR mutations and the antitumour activity and prolonged
survival with gefitinib has been reported (Han et al, 2005;
Mitsudomi et al, 2005), we conducted analysis on these two types
of mutations only. Our results were compatible with those from
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Figure 1 Kaplan–Meier plots of survival for patients receiving gefitinib treatment classified according to (A) PS, (B) histology, (C) smoking status and (D)
EGFR gene mutation status.
Table 3a COX Proportional Hazard Model for Survival Analysis in
Overall Population (N¼221)
Variable HR 95%CI P–value
Never-smoker/Ever-smoker 0.413 0.294–0.582 o0.001
Adeno/Non-adeno 0.416 0.265–0.654 o0.001
PS 0, 1/2–4 0.205 0.145–0.291 o0.001
Stepwise method (include o0.05, exclude 40.2). Tested variables; gender, smoking,
histology, PS, excluded variable; gender.
Table 3b COX proportional hazard model for survival analysis in
patients in which EGFR mutation status has been detected (n¼91)
Variable HR 95%CI P-value
Adeno/Non-adeno 0.581 0.288–1.171 0.129
Never-smoker /ever-smoker 0.607 0.351–1.048 0.073
Mutation negative/positive 2.543 1.345–4.808 0.004
PS 0, 1/2–4 0.166 0.091–0.303 o0.001
Tested variables; gender, smoking, histology, PS, mutation excluded variable; gender.
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Figure 2 Survival stratified by smoking exposure (classified by BI).
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mutation (Inoue et al, 2006; Okamoto et al, 2006). Epidermal
growth factor receptor mutation therefore appears to be a more
specific criterion for gefitinib use than patient selection according
to clinical characteristics.
The relatively high incidence of ILD (3.5–5.8%) in patients treated
with gefitinib has been reported in Japan. It also revealed that male
gender, ever-smokers, poor PS and the coincidence of interstitial
pneumonia were predictive factors for the development of ILD
(Yoshida, 2005; Ando et al, 2006). Although these predictive factors
contrast with those for the presence of an EGFR mutation, two of the
28 patients with an EGFR mutation developed ILD in our study.
In our examination of prognostic factors, we analysed the
relationship particularly between smoking status (ever-/never-smoker,
smoking exposure) and two types of EGFR mutations, as well as
the relationship between smoking status and EGFR mutation. Our
findings indicated that patients with EGFR mutation had
significantly longer MST in both ever- and never-smokers, and
there was no significant difference in MST between ever- and
never-smokers with the same mutation status. This led to the
conclusion that the essential factor associated with survival is
EGFR mutation status. Though better MST has been reported in
L858R cases in a comparison of survival between exon 19 deletion
and L858R missense (Shigematsu et al, 2005), recent reports have
shown better survival in patients with exon 19 deletion (Jackman
et al, 2006; Riely et al, 2006). Incidentally, we found MST to be
better in L858R cases. As reported by Jackman et al (2006), RR was
more favourable among the exon 19 deletion cases. Although this
was conceivably due to factors including the ILD being experi-
enced in two cases with exon 19 deletion and the impact of post-
gefitinib treatment, the relatively small sample did not allow for
any clarification in this respect.
Our data also show that the larger the smoking exposure, the
shorter the survival.
There have been several reports of an inverse correlation
between smoking exposure and EGFR mutation rate (Han et al,
2005; Pham et al, 2006; Sugio et al, 2006; Tam et al, 2006; Toyooka
et al, 2006). In line with these studies, our data show that smoking
status, unlike EGFR mutation status, is not an independent
prognostic factor. Considered in combination with past reports on
smoking exposure and EGFR mutation rates, the inverse correla-
tion between smoking exposure and MST shown by our data might
conceivably reflect that mutation rates differ according to smoking
exposure. They also indicate that smoking status is a very powerful
surrogate marker of EGFR mutation status, which is a prognostic
factor for prolonged survival with gefitinib treatment. Our
multivariate analysis in terms of clinical characteristics indicates
that smoking status is a significant predictor. However, the
multivariate analysis adding EGFR mutation status eliminates the
significant difference with regard to smoking, demonstrating that
EGFR mutation status and PS 0–1 are independent prognostic
factors. This also suggests that ECOG PS and EGFR mutation status
are factors that can be used to predict the intrinsic effect of
gefitinib on patients as well as their prognosis, supporting the
claim that smoking could be a surrogate marker of EGFR mutation
status for prediction of survival benefit. Although RR in never-
smokers and cases with EGFR mutation on erlotinib, which is
also an EGFR-TKI, has been significantly favourable, there has
only been marginal significant interaction between survival and
smoking status (Clark et al, 2006). However, no significant
differences have been reported in regard to EGFR mutation status,
and detection of the EGFR mutation is considered unnecessary
in treatment using erlotinib (Tsao et al, 2005; Clark et al, 2006).
Our results showing that EGFR mutation and smoking status can
function as predictors of survival benefit differ from reports on
erlotinib. However, they concur with reports to date on gefitinib,
presumably suggesting the necessity to select patients before using
gefitinib. Further clinical studies are warranted to examine the
survival benefits of gefitinib according to EGFR mutation status,
that is, to make the EGFR mutation status an inclusion criterion.
Considerations should be made in clinical practise to analyse
actively EGFR mutations status where possible. However, it is often
very difficult to obtain histological specimens of advanced and
recurrent lung cancer for which gefitinib is indicated. In fact,
in this study we were only able to obtain analytical results for
EGFR mutation status for 91 out of 221 (42%) patients. Another
problem is EGFR mutation analysis takes time, about 1–3 weeks,
necessitating a wait-time before treatment. Therefore, when a
certain clinical environment does not allow for, or complicates the
detection of EGFR mutations, smoking exposure/smoking status
could be a quick and inexpensive reference as a surrogate marker
of EGFR mutation status. In future, it will be necessary to evaluate
the survival benefits of gefitinib via a Phase III study in patients
with these better predictive factors.
IRESSA is a trademark of the AstraZeneca group of companies.
REFERENCES
Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi
Y, Fukuoka M (2006) Predictive factors for interstitial lung disease,
antitumor response, and survival in non-small-cell lung cancer patients
with gefitinib. J Clin Oncol 24: 2549–2556, doi:10.1200/JCO.2005.04.9866
Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour
L, Shepherd FA (2006) Smoking history and epidermal growth factor
receptor expression as predictors of survival benefit from erlotinib for
patients with non-small-cell lung cancer in the National Cancer Institute
of Canada clinical trials group study BR.21. Clin Lung Cancer 7: 389–394
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY,
Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Harai T, Noda
K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP,
Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib
for previously treated patients with advanced non-small-cell lung cancer
(The IDEAL 1 trial). J Clin Oncol 21: 2237–2246, doi:10.1200/
JCO.2003.10.038
Han S, Kim T, Hwang PG, Jeong S, Kim J, Choi IS, Oh D-Y, Kim JH, Kim
D-W, Chung DH, Im S-A, Kim YT, Lee JS, Heo DS, Bang Y-J, Kim NK
(2005) Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small-cell lung cancer patients treated with
gefitinib. J Clin Oncol 23: 2493–2501, doi:10.1200/JCO.2005.01.388
Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N,
Watanabe H, Saijo Y, Nukiwa T (2006) Prospective phase II study of
gefitinib for chemotherapy-naı ¨ve patients with advanced non-small-cell
lung cancer with epidermal growth factor receptor gene mutations. J Clin
Oncol 24: 3340–3346, doi:10.1200/JCO.2005.05.4692
0.0118 7.3 42 24.9 11 Ever
smoker
Log-
rank
Mutation
negative
Mutation
positive
8.0
MST
0.3412
21
N
0.8638
17
N
0.0141 34.5 Never
smoker
Log-rank
MST Smoking
(MST)
Time (months)
50 40 30 20 10 0
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Figure 3 Survival stratified by smoking status and EGFR gene mutation
status.
Predictors of survival benefits with gefitinib
M Satouchi et al
1195
British Journal of Cancer (2007) 96(8), 1191–1196 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sJackman DM, Yeap B, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell
DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ,
Mayerson M, Johnson BE, Ja ¨nne PA (2006) Exon 19 deletion mutation of
epidermal growth factor receptor are associated with prolonged survival
in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Clin Cancer Res 12: 3908–3914, doi:10.1158/1078-0432.CCR-05-0462
Kim K-S, Jeong J-Y, Kim Y-C, Na K-J, Kim Y-H, Ahn S-J, Baek S-M, Park
C-S, Park C-M, Kim Y-I, Lim S-C, Park K-O (2005) Predictors of the
response to gefitinib in refractory non-small-cell lung cancer. Clin
Cancer Res 11: 2244–2251
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T
(2004) Mutations of the epidermal growth factor receptor gene in lung
cancer: biological and clinical implications. Cancer Res 64: 8919–8923
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH,
Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK,
Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy and safety of gefitinib
(ZD1839, Iressat), an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell lung cancer:
a randomized trial. JAMA 290: 2149–2158
Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Hong EK, Lee JS (2005)
A Phase II study of gefitinib (ZD1839; Iressa) as a first-line therapy for
never-smoker with adenocarcinoma or metastatic adenocarcinoma of the
lung. J Clin Oncol 23: 638s (suppl; abstr 7072)
Lim S-T, Wong E-H, Chuah K-L, Leong S-S, Lim W-T, Tay M-H, Toh C-K,
Tan E-H (2005) Gefitinib is more effective in never-smokers with non-
small-cell lung cancer: experience among Asian patients. Br J Cancer 93:
23–28, doi:10.1038/sj.bjc.6602652
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan
BW, Harris PL, Haserlat SM, Supko JG, Haruska FG, Louis AN, Christiani
DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung
cancer to gefitinib. N Engl J Med 350: 2129–2139
Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Kruz LM, Pao W,
Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N,
Zakowski M, Rusch V, Heelan RT (2004) Bronchioloalveolar pathologic
subtypes and smoking history predict sensitivity to gefitinib in advanced
non-small-cell lung cancer. J Clin Oncol 22: 1103–1109, doi:10.1200/
JCO.2004.08.158
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S,
Shinoda M, Takahashi T, Yatabe Y (2005) Mutations of epidermal growth
factor receptor gene predict prolonged survival after gefitinib treatment
in patients with non-small-cell lung cancer with postoperative recur-
rence. J Clin Oncol 23: 2513–2520, doi:10.1200/JCO.2005.00.992
Okamoto I, Kashii T, Urata Y, Hirashima T, Kudoh S, Ichinose Y, Ebi N,
Satoh T, Tamura K, Fukuoka M (2006) EGFR mutation-based phase II
multicenter trial of gefitinib in advanced non-small cell lung cancer
(NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group
trial (WJTOG0403). J Clin Oncol 24: 18s (suppl; abstr 7073)
Paez JG, Ja ¨nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye
FJ, Lindeman N, Boggan T, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers
WR, Johnson BE, Meyerson M (2004) EGFR mutation in lung cancer:
correlation with clinical response to gefitinib therapy. Science 304:
1497–1500
Pao W, Miller V, Zakowski M, Doherty J, Polti K, Sarkaria I, Singh B,
Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M,
Varmus H (2004) EGF receptor gene mutations are common in lung
cancer from ‘never smokers’ and are associated with sensitivity of
tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–
13311, doi: 10.1073/pnas.0405220101
Pham DP, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S,
Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B,
Rusch VW (2006) Use of cigarette-smoking history to estimate the
likelihood of mutations in epidermal growth factor receptor gene exons
19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700–1704,
doi:10.1200/JCO.2005.04.3224
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF,
Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with
non-small cell lung cancer and epidermal growth factor receptor exon 19
and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res
12: 839–844, doi:10.1158/1078-0432.CCR-05-1846
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong
KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J,
Minna JD, Bazdar AF (2005) Clinical and biological features associated
with epidermal growth factor receptor gene mutation in lung cancers.
J Natl Cancer Inst 97: 339–346, doi: 10.1093/jnci/dji055
Sonobe M, Manabe T, Wada H, Tanaka F (2005) Mutations in the epidermal
growth factor receptor gene are linked to smoking-independent, lung
adenocarcinoma. Br J Cancer 93: 355–363, doi:10.1038/sj.bjc.6602707
Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki Y, So
T, Nakata S, Morita M, Yasuoto K (2006) Mutations within the tyrosine
kinase domain of EGFR gene specifically occur in lung adenocarcinoma
patients with a low exposure of tobacco smoking. Br J Cancer 94:
896–903, doi:10.1038/sj.bjc.6603040
Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu
SW, Girad L, Minna JD, Gazdar AF, Wong MP (2006) Distinct epidermal
growth factor receptor and KRAS mutation patterns in non-small cell
lung cancer patients with different tobacco exposure and clinicopatho-
logic features. Clin Cancer Res 12: 1647–1653
Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, Pawel J,
Thongprasert S, Tan EH, Pemberton K, Archer V, Carrol K (2005)
Gefitinib plus best supportive care in previously treated patients with
refractory advanced non-small-cell lung cancer: results from a rando-
mized, placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet 36: 1527–1537
Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura
K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date
H, Gazder AF, Shimizu N (2005) The relationship between epidermal
growth factor receptor mutations and clinicopathologic features in non-
small cell lung cancers. Clin Cancer Res 11: 1167–1173
Toyooka S, Tokumo M, Shigenatsu H, Matsuo K, Asano H, Tomii K,
Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N (2006)
Mutational and epigenetic evidence for independent pathways for lung
adenocarcinomas arising in smokers and never smokers. Cancer Res 66:
1371–1375
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I,
Zhang T, Liu N, Daneshmand M, Marrano P, Santos GC, Lagarde A,
Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA
(2005) Erlotinib in lung cancer-molecular and clinical predictors of
outcome. N Engl J Med 353: 133–144
Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T (2006) A
rapid, sensitive assay to detect EGFR mutation in small biopsy specimens
from lung cancer. J Mol Diagn 8: 335–341
Yoshida S (2005) The results of gefitinib prospective investigation.
Med Drug J 41: 772–789
Predictors of survival benefits with gefitinib
M Satouchi et al
1196
British Journal of Cancer (2007) 96(8), 1191–1196 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s